Former US Food and Drug Administration commissioner Scott Gottlieb's recent election to Pfizer Inc.'s board of directors is just a reminder of how highly sought-after FDA heads are by a broad array of stakeholders once they leave their government post.
Gottleib's post-agency move was in keeping with the tenor of his behavior when he was commissioner: swift and high-profile, but not really out of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?